The biotech says its potentially life-saving drug is drawing increasing interest from major pharmaceutical companies in China, where stroke is now the leading cause of death.
Cheyanne Enciso
WA biotech PYC Therapeutics is tapping shareholders for up to $146 million to fund the development of its four drug candidates.
Low immunisation rates in the US have dented first-half sales for CSL’s flu vaccine business, but the biotech giant says it’s on track to deliver double-digit earnings growth this year.
Alan Tribe-chaired PYC Therapeutics has received regulatory approval to commence human trials for its drug aimed at addressing polycystic kidney disease.
WA telehealth startup BlinkLab has secured its first clinical trial site in the US as it works towards a Food and Drug Administration approval.
WA biotech Orthocell will accelerate plans to enter five new markets this year, buoyed by the early sales traction recorded in Australia, New Zealand and Singapore for its flagship nerve repair product.
Rohan Hockings believes his $600 million WA biotech is edging closer to success after nearly 20 years of life on the Australian Securities Exchange.
Having raised cash from the likes of Chris Ellison, Rod Jones, the McCusker family and Chris Judd, the fast-running biotech stock has been among the ASX’s best performers over the past six weeks.
Sean Smith
Incoming Neurotech boss Anthony Filippis wants to set his feet firmly under the table by fast-tracking the WA biotech’s bid to secure global partnerships for its oral cannabinoid drug therapy.
WA biotech Botanix has shipped the first batch of its sweat-stopper gel to US patients six months after securing Food and Drug Administration approval.
WA biotech Orthocell has started selling its nerve repair product in Singapore, two months after the company received regulatory approval in the country.
A biomedical engineer is set to offer people living with disability a level of independence as easy as looking left and right.
Hannah Cross
Australia’s largest biotech company delivered a 750 per cent return for investors in the decade before the onset of COVID-19. It's shares have since plateaued. What happened?
Amy Bainbridge and Jason Gale
WA biotech Neurotech International has won vital ethics approval for its cannabinoid drug therapy aimed at treating neurological disorders in children.
Strengthening WA’s entrepreneurial ecosystem could see 350 new startups and create as many as 3500 highly skilled jobs, Bankwest Curtin Economics Centre has claimed in a new report.
The nerve-repair company’s shares have been on a tear after a series of positive regulatory and operating updates.
Shares in regenerative medicine company Orthocell soared after the company received regulatory approval for its nerve repair product in Singapore.
A WA listed biotech has failed in its bid to get major backing from the US Food and Drug Administration for its cannabinoid drug therapy aimed at treating neurological disorders in children.
WA regenerative medicine company Orthocell has started selling its dental bone repair product in Canada — a market estimated to worth to be about $60 million.
Symex Labs is eyeing first human trials for its wearable fertility hormone tracker in as little as two years, with new inventions like it predicted to boost revenues at fertility clinics to $900 million.
CSL is forecasting double-digit earnings growth this year underpinned by its key immunoglobulins franchise but the biotech giant warned revenue growth will be on the lower end.
WA patients have become the first in the world to access a novel nasal spray treatment for erectile dysfunction, developed by Brisbane-based biotech LTR Pharma that is promising results in 10 minutes.
The bosses of WA biotech companies Argenica Therapeutics and PYC Therapeutics are confident of its ability to bring more investors for the ride amid a challenging period for the nascent sector.
Shares in WA regenerative medicine company Orthocell are up after it received regulatory approval to start selling its dental bone repair product in Canada.
We use cookies so we can improve your experience on this site, analyse traffic and provide you with relevant advertising. To find out more, please see our Cookies Guide.
By continuing to use this site, you agree to our use of cookies.
